Hypertension Diagnostics, Inc. (OTCMKTS:HDII) Files An 8-K Changes in Control of Registrant
Item 5.01 Changes in Control of Registrant
On May 24th , 2019, Mr. Liangjian Peng, through a Stock Purchase Agreement, received 3 Million Preferred shares controlling shares with voting rights and conversion of 1:1000 common shares of the company stock.
Item 8.01 Other Events
Hypertension Diagnostics, Inc. intends to file the last two annual reports in an effort to get current with the OTC Markets and for full disclosure to stockholders of company business.
About Hypertension Diagnostics, Inc. (OTCMKTS:HDII)
Hypertension Diagnostics, Inc. designs, develops, manufactures and markets noninvasive medical devices that detect subtle changes in the elasticity of arteries. The Company offers CVProfilor DO-2020, CVProfilor MD-3000 and HD/PulseWave CR-2000. The CVProfilor DO-2020 is a non-invasive System designed to provide physicians in the United States with a means for assessing a patient’s vascular health. The CVProfilor DO-2020 provides a patient’s arterial elasticity indices, which can be used in the assessment for underlying vascular disease. The CVProfilor MD-3000 provides a guide to the presence of blood vessel disease. The HD/PulseWave CR-2000 is a non-invasive System designed for research purposes. The HD/PulseWave CR-2000 Research CardioVascular Profiling System provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in a range of areas, including pharmaceutical studies, endothelial function, aging and women’s health.